At a median follow-up of 8.7 months, the average progression-free survival, which is the time from treatment until disease worsens, was 5.8 months in the Rivoceranib group, compared with 3.3 months ...

The safety analysis included all 53 patients enrolled in the trial. Treatment-related adverse events (TRAEs) occurred in 18 (78.3%) patients in the paclitaxel group and 19 (63.3%) of the PLD group.

What Patti Drinville, The PLD Group, likes most about the RISO presses is their smaller footprint, fast speeds, phenomenal quality. Continue to your page in 15 seconds or skip this ad . Printing ...

In the GEM or PLD group, neutrophil count decreased was the most common grade 3 or 4 TRAE, occurring in 62 patients (40.0%), compared with one patient in the nivolumab group (0.6%). irAEs (any grade) ...